2012 Annual Meeting | Clinical Issues in Multiple Sclerosis
| 08:00 AM - 08:15 AM |
Debate #1: Resolved That MRI is a Suitable Endpoint for Phase III MS Trials for Relapsing-Remitting MS, Replacing Attacks/Disability: Affirmative Argument
Dean M. Wingerchuk, MD, FAAN |
|
| 08:15 AM - 08:30 AM |
Debate #1: Resolved That MRI is a Suitable Endpoint for Phase III MS Trials for Relapsing-Remitting MS, Replacing Attacks/Disability: Negative Argument
Alex D. Rae-Grant, MD, FAAN |
|
| 08:30 AM - 08:50 AM |
Debate #1: Rebuttals and Summary
|
|
| 08:50 AM - 09:05 AM |
Cost-effectiveness: Is It an Informative Way to Assess the Clinical Value of Disease-Modifying Treatments in MS?
Dean M. Wingerchuk, MD, FAAN |
|
| 09:05 AM - 09:20 AM |
Debate #2: Resolved that MS Treatments Vary in Effectiveness Based On Whether the Immune System Is Th1 or Th17 Polarized: Affirmative Argument
Brian G. Weinshenker, MD, FAAN |
|
| 09:20 AM - 09:35 AM |
Debate #2: Resolved that MS Treatments Vary in Effectiveness Based On Whether the Immune System Is Th1 or Th17 Polarized: Negative Argument
Alasdair Coles, MD, PhD |
|
| 09:35 AM - 09:55 AM |
Debate #2: Rebuttals and Summary
|
|
| 09:55 AM - 10:10 AM |
Break
|
|
| 10:10 AM - 10:25 AM |
Dalfampridine: How Valuable Is It for Treatment of Patients with MS-related Impairment?
Alex D. Rae-Grant, MD, FAAN |
|
| 10:25 AM - 10:40 AM |
B-cells vs T-cells in MS: Are B-cell Directed Treatments as Good as T-cell Directed? Are They Better for Some Patients than for Others?
Alasdair Coles, MD, PhD |
|
| 10:40 AM - 12:00 PM |
Interactive Case Discussions: Diagnostic Difficulties, Early Management Controversies and Treatment of Refractory Cases
Brian G. Weinshenker, MD, FAAN, Dean M. Wingerchuk, MD, FAAN |
| Alex D. Rae-Grant, MD, FAAN | Dr. Rae-Grant has received publishing royalties from a publication relating to health care. Dr. Rae-Grant has received publishing royalties from a publication relating to health care. |
| Brian G. Weinshenker, MD, FAAN | Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care. |
| Dean M. Wingerchuk, MD, FAAN | Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TTY Biopharm. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Biopharm. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers. |
| Alasdair Coles, MD, PhD | Dr. Coles has nothing to disclose. |